NIKKEI 225
26,564.86 -239.74 (-0.89%) HANG SENG
21,948.90 -47.99 (-0.22%) CRUDE OIL
109.97 +0.19 (+0.17%) GOLD FUTURES
1,821.10 +3.60 (+0.20%) DOW
31,029.31 +82.32 (+0.27%) BTC-GBP
16,531.41 -265.43 (-1.58%)
Biogen Inc. (BIIB.MX)
| Previous close | 4,021.00 |
| Open | 4,067.33 |
| Bid | 4,067.33 x 100 |
| Ask | 0.00 x 100 |
| Day's range | 4,067.33 - 4,067.33 |
| 52-week range | 3,880.00 - 7,356.00 |
| Volume | |
| Avg. volume | 55 |
| Market cap | 607.984B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 19.40 |
| EPS (TTM) | 209.61 |
| Earnings date | 20 Apr 2022 - 25 Apr 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,
- Zacks
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Zacks
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
